Addition of cyclophosphamide “on demand” to lenalidomide and corticosteroids in patients with relapsed/refractory multiple myeloma – A retrospective review of a single centre experience
ConclusionThe addition of Cy in patients with myeloma progressing on Len-dex was an inexpensive option with manageable toxicity that resulted in a clinically meaningful extension of disease control.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Corticosteroid Therapy | Dexamethasone | Leukemia | Lymphoma | Myeloma | Oral Cancer | Revlimid | Toxicology